171 related articles for article (PubMed ID: 24521833)
1. The clinical use of granulocyte-colony stimulating factor.
Shah J; Welsh SJ
Br J Hosp Med (Lond); 2014 Feb; 75(2):C29-32. PubMed ID: 24521833
[No Abstract] [Full Text] [Related]
2. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience.
Cerchione C; Catalano L; Pareto AE; Picardi M; Pane F
Support Care Cancer; 2015 Feb; 23(2):301-2. PubMed ID: 25341551
[No Abstract] [Full Text] [Related]
5. Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patients.
Danova M; Antonuzzo A; Spandonaro F; Pronzato P
Infez Med; 2020 Mar; 28(1):127-129. PubMed ID: 32172272
[TBL] [Abstract][Full Text] [Related]
6. [Primary and secondary prophylactic administration of granulocyte-colony stimulating factor(G-CSF)for febrile neutropenia].
Uchino K; Baba E
Gan To Kagaku Ryoho; 2014 Jun; 41(6):691-3. PubMed ID: 25129081
[TBL] [Abstract][Full Text] [Related]
7. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.
Trotta F; Mayer F; Mecozzi A; Amato L; Addis A
BioDrugs; 2017 Apr; 31(2):117-124. PubMed ID: 28353170
[TBL] [Abstract][Full Text] [Related]
8. The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.
Klastersky J; Raftopoulos H; Rapoport B
Support Care Cancer; 2013 Jun; 21(6):1793-5. PubMed ID: 23525960
[No Abstract] [Full Text] [Related]
9. Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years.
Edelsberg J; Weycker D; Bensink M; Bowers C; Lyman GH
Curr Med Res Opin; 2020 Mar; 36(3):483-495. PubMed ID: 31834830
[TBL] [Abstract][Full Text] [Related]
10. Colony-stimulating factors for febrile neutropenia during cancer therapy.
Bennett CL; Djulbegovic B; Norris LB; Armitage JO
N Engl J Med; 2013 Mar; 368(12):1131-9. PubMed ID: 23514290
[TBL] [Abstract][Full Text] [Related]
11. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Gebremariam GT; Fentie AM; Beyene K; Sander B; Gebretekle GB
BMC Health Serv Res; 2022 Dec; 22(1):1600. PubMed ID: 36585648
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
14. Myeloid growth factors.
Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
[No Abstract] [Full Text] [Related]
15. Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.
Keating GM
Drugs; 2011 Apr; 71(6):679-707. PubMed ID: 21504247
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
Cortés de Miguel S; Calleja-Hernández MÁ; Menjón-Beltrán S; Vallejo-Rodríguez I
Support Care Cancer; 2015 Feb; 23(2):547-59. PubMed ID: 25284722
[TBL] [Abstract][Full Text] [Related]
17. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
Baig H; Somlo B; Eisen M; Stryker S; Bensink M; Morrow PK
J Oncol Pharm Pract; 2019 Oct; 25(7):1576-1585. PubMed ID: 30200842
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
19. Commentary - A comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars and Intended Copy Biologics in treating chemotherapy associated febrile neutropenia.
Cornes PG; Muenzberg M
Toxicol Appl Pharmacol; 2020 Nov; 406():115202. PubMed ID: 32822736
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the impact of timing of pegfilgrastim administration on incidence of febrile neutropenia in elderly patients with B-cell non-Hodgkin lymphomas receiving R-CHOP-21.
Lei MM; Watson AN; Abramson JS
Leuk Lymphoma; 2020 Dec; 61(12):2998-3001. PubMed ID: 32686543
[No Abstract] [Full Text] [Related]
[Next] [New Search]
